Filing identity and reporting period
The supplied filing is Onconova Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2014, not a filing identified in its text as Traws Pharma, Inc. Investors should verify the company and filing before relying on this summary. Onconova was a clinical-stage oncology biopharmaceutical company with three clinical-stage candidates and six preclinical programs.
Financial results and liquidity
| Metric | Q1 2014 | Q1 2013 or comparison |
|---|---|---|
| Revenue | $447,000 | $1.116 million |
| Operating expenses | $19.180 million | $16.102 million |
| Research and development | $14.248 million | $12.756 million |
| General and administrative | $4.932 million | $3.346 million |
| Net loss | $18.716 million | $14.845 million |
| Net loss per share | $0.87 | $6.08 |
| Operating cash used | $16.165 million | $13.949 million |
Gross profit and operating margins are not separately presented; revenue was small relative to operating expenses. At March 31, 2014, cash and cash equivalents were $54.624 million and marketable securities were $29.999 million, totaling $84.623 million, versus $100.003 million at December 31, 2013. Working capital was $77.5 million. Total liabilities were $25.354 million, including $11.556 million of current liabilities and $14.250 million of deferred revenue. The balance sheet presents no borrowings line item; the filing text does not provide a separate debt total.
Cash decreased $5.385 million during the quarter. Operating cash use was partly offset by $9.928 million of investing cash inflow, primarily $10.0 million from maturities of marketable securities, and $853,000 from option exercises. Accumulated deficit was $249.575 million.
Material changes versus the prior-year quarter
- Revenue fell $669,000, primarily because less Baxter-related research and development revenue was recognized as covered activities declined.
- Operating expenses rose $3.078 million and net loss widened $3.871 million. G&A increased 47%, mainly reflecting public-company costs, pre-commercialization consulting and higher staffing. R&D rose 12%, driven by personnel and manufacturing/formulation work, partly offset by lower clinical costs and consulting.
- Other income declined $126,000, mainly because Q1 2013 included proceeds related to the conversion of the company’s insurance provider from a mutual to a stock company.
- Weighted-average shares rose to 21.568 million from 2.607 million, following the 2013 IPO and conversion of preferred stock. Accordingly, the lower reported loss per share is not a like-for-like indication of improved operating performance.
Outlook, risks and unusual items
- Management said existing capital resources were expected to fund operations for at least the next 12 months, but substantial additional financing would be needed in the future. The company expected continued losses and negative operating cash flow; additional financing might be unavailable or dilutive.
- Rigosertib Phase 3 higher-risk MDS results showed a numerical 2.4-month median overall-survival improvement that did not meet statistical significance. Management noted a potentially encouraging result in the subset previously treated unsuccessfully with hypomethylating agents and planned discussions with regulators. The pancreatic cancer Phase 3 study had been discontinued after an interim futility and safety analysis.
- Management planned to resume Phase 1 development of briciclib in 2014. Recilisib was being developed with the U.S. Department of Defense; timing and outcomes for these programs remained uncertain.
- Potential Baxter and SymBio milestones and royalties depend on development, regulatory and sales outcomes and are not assured. LLS funding received was recorded as deferred revenue because of a potential repayment contingency; the filing describes a capped payment obligation tied to future events.
- Disclosure controls were deemed ineffective at the reasonable-assurance level because a previously identified material weakness in financial reporting had not been fully remediated. The filing reported no material legal proceedings and no material changes to the risk factors in the prior 10-K.
Important facts for investors to verify
- Confirm the filing’s registrant: the text identifies Onconova Therapeutics, Inc., whereas the request metadata identifies Traws Pharma, Inc.
- Review subsequent clinical and regulatory updates on rigosertib, especially the higher-risk MDS trial analyses and planned regulatory discussions.
- Assess cash burn, financing needs and the assumptions behind management’s estimate of at least 12 months of funding capacity.
- Check progress toward remediating the material weakness and improving disclosure controls.
- Verify the status and terms of Baxter, SymBio and LLS arrangements, including potential milestones, royalties and contingent obligations.